GlassScriptPhysician profile
Roger J Miller
NPI 1841262987
$6,759.87
in general payments reported to CMS, 2019-2025
36 companies · $85.03 in 2025
The $85.03 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,540 · 2020: $1,504 · 2021: $2,112 · 2022: $1,332 · 2023: $93.74 · 2024: $93.62 · 2025: $85.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $272.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $592.95 | 2019-2022 | |
| Astellas Pharma US INC | $536.79 | 2019-2022 | |
| Novo Nordisk INC | $524.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.79 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $493.48 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Astrazeneca Pharmaceuticals LP | $482.77 | 2019-2022 | |
| Lilly USA, LLC | $478.64 | 2019-2022 | |
| Amgen INC. | $448.08 | 2019-2022 | |
| Abbvie INC. | $411.99 | 2020-2022 | |
| Pfizer INC. | $320.48 | 2019-2023 | |
| Antares Pharma, INC. | $287.00 | 2019-2022 | |
| Glaxosmithkline, LLC. | $236.95 | 2019-2024 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $210.42 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $195.94 | 2021 | |
| Abbott Laboratories | $169.77 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $122.19 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.61 | 2019-2022 | |
| Eisai INC. | $73.02 | 2020-2022 | |
| Clarus Therapeutics INC. | $70.45 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.69 | 2020 | |
| Jazz Pharmaceuticals INC. | $45.49 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $45.00 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $43.43 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $39.13 | 2022 | |
| Sanofi-Aventis U.S. LLC | $38.35 | 2022 | |
| Hologic Sales and Service, LLC | $32.27 | 2020-2022 | |
| Daiichi Sankyo INC. | $28.48 | 2025 | Injectafer |
| Arbor Pharmaceuticals, INC. | $26.89 | 2019-2020 | |
| Adlon Therapeutics L.P. | $23.81 | 2020-2021 | |
| Exact Sciences Corporation | $20.24 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $18.58 | 2020 | |
| Tolmar, INC. | $18.02 | 2023 | |
| Horizon Therapeutics Plc | $16.91 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.85 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.01 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.